IOVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Iovance Biotherapeutics Inc (IOVA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has shown strong revenue growth, operational improvements, and positive clinical trial results, which indicate significant long-term potential. Despite short-term price declines, the stock appears undervalued based on analyst upgrades and positive sentiment.
The MACD is positive and expanding, indicating bullish momentum. The RSI is overbought at 90.152, suggesting caution for short-term traders, but the long-term trend remains positive with bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 4.006 and 4.451, while support levels are at 2.566 and 2.121.
FDA Fast Track designation for lifileucel in lung cancer.
Positive clinical trial results with a 50% response rate for soft tissue sarcomas.
Significant revenue growth (30% sequentially in Q4
and operational improvements.
Analysts have raised price targets, with some viewing the stock as undervalued.
Hedge funds are significantly increasing their positions.
Short-term price decline (-1.04% regular market, -2.50% post-market).
Negative EPS (-$0.
and net income (-$71.9M) in Q4 2025, though improving YoY.
Overbought RSI, indicating potential short-term pullback.
In Q4 2025, Iovance reported revenue growth of 17.74% YoY to $86.7M, driven by strong product performance. Gross margins improved to 50%, reflecting operational efficiency. However, net income remained negative at -$71.9M, though it improved by 8.47% YoY. EPS also improved to -$0.18 from -$0.26 YoY.
Analysts are generally positive on IOVA. Baird raised its price target to $4, Citizens upgraded to Outperform with a $5 target, Barclays raised its target to $11, and Chardan maintained a Buy rating with a $16 target. Goldman Sachs remains bearish with a $2 target, but this is an outlier. Overall, analysts see the stock as undervalued with strong growth potential.
